Down 21.4% in 4 Weeks, Here's Why Health Catalyst (HCAT) Looks Ripe for a Turnaround

Impact · against what's priced in

Health Catalyst (HCAT) shows strong fundamental and technical signals for a reversal, driven by a 128.1% increase in consensus EPS estimates and an oversold RSI of 28.93. While recent price momentum is negative, the divergence between earnings revisions and the 21.4% price drop suggests a potential turnaround.

HCAT+0.40

No priced-in read yet